The aim of the study was to compare the clinical efficacy and safety of the on-demand
use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in
treatment of patients with premature ejaculation (PE). In a single-blind
clinical study, 150 PE patients without erectile dysfunction (ED) were included
during the period of March 2015 to May 2016. Patients were randomly divided
into five groups (30 patients each). On demand placebo, paroxetine (30 mg), dapoxetine
(30 mg), sildenafil citrate (50 mg) and combined dapoxetine (30 mg) with sildenafil
citrate (50 mg) were given for patients for 6 weeks in each group respectively. All patients
were instructed to record intravaginal ejaculatory latency time (IELT) and evaluated
with Premature Ejaculation Diagnostic Tool (PEDT) and the patient satisfaction
score before and after treatment. The mean of IELT, satisfaction score and PEDT in all
groups was significantly improved after treatment (p value = .001). Combined dapoxetine
with sildenafil group had the best values of IELT, satisfaction scores and PEDT in
comparison with other treatment groups (p value <.001). The combined dapoxetine
with sildenafil therapy could significantly improve PE patients without ED as compared
to paroxetine alone or dapoxetine alone or sildenafil alone with tolerated adverse